Annual SG&A
$49.94 M
+$12.40 M+33.05%
31 December 2023
Summary:
Verve Therapeutics annual selling, general & administrative expenses is currently $49.94 million, with the most recent change of +$12.40 million (+33.05%) on 31 December 2023. During the last 3 years, it has risen by +$44.68 million (+850.08%). VERV annual SG&A is now at all-time high.VERV Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$13.84 M
-$710.00 K-4.88%
30 September 2024
Summary:
Verve Therapeutics quarterly selling, general & administrative expenses is currently $13.84 million, with the most recent change of -$710.00 thousand (-4.88%) on 30 September 2024. Over the past year, it has increased by +$2.15 million (+18.41%). VERV quarterly SG&A is now -4.88% below its all-time high of $14.55 million, reached on 30 June 2024.VERV Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$2.47 B
-$197.03 M-8.66%
30 September 2024
Summary:
Verve Therapeutics TTM selling, general & administrative expenses is currently -$2.47 billion, with the most recent change of -$197.03 million (-8.66%) on 30 September 2024. Over the past year, it has dropped by -$2.52 billion (-5137.73%). VERV TTM SG&A is now -3617.04% below its all-time high of $54.83 million, reached on 30 September 2024.VERV TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VERV Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +33.0% | +18.4% | -5137.7% |
| 3 y3 years | +850.1% | +130.3% | -10000.0% |
| 5 y5 years | - | - | - |
VERV Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +850.1% | -4.9% | +130.3% | -469.1% | at low |
| 5 y | 5 years | at high | +1899.0% | -4.9% | +1535.6% | -3617.0% | at low |
| alltime | all time | at high | +1899.0% | -4.9% | +1535.6% | -3617.0% | at low |
Verve Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $13.84 M(-4.9%) | $54.83 M(+4.1%) |
| June 2024 | - | $14.55 M(+2.7%) | $52.68 M(+2.2%) |
| Mar 2024 | - | $14.16 M(+15.3%) | $51.55 M(+3.2%) |
| Dec 2023 | $49.94 M(+33.0%) | $12.28 M(+5.1%) | $49.94 M(+1.7%) |
| Sept 2023 | - | $11.69 M(-12.9%) | $49.09 M(+4.5%) |
| June 2023 | - | $13.42 M(+6.9%) | $47.00 M(+10.2%) |
| Mar 2023 | - | $12.55 M(+9.7%) | $42.65 M(+13.6%) |
| Dec 2022 | $37.53 M | $11.44 M(+19.2%) | $37.53 M(+14.8%) |
| Sept 2022 | - | $9.59 M(+5.8%) | $32.70 M(+12.3%) |
| June 2022 | - | $9.07 M(+22.0%) | $29.11 M(+23.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $7.43 M(+12.6%) | $23.58 M(+25.0%) |
| Dec 2021 | $18.86 M(+258.9%) | $6.60 M(+9.9%) | $18.86 M(+32.0%) |
| Sept 2021 | - | $6.01 M(+69.6%) | $14.29 M(+48.3%) |
| June 2021 | - | $3.54 M(+30.4%) | $9.63 M(+35.2%) |
| Mar 2021 | - | $2.72 M(+34.2%) | $7.13 M(+35.6%) |
| Dec 2020 | $5.26 M(+110.4%) | - | - |
| Dec 2020 | - | $2.02 M(+49.5%) | $5.26 M(+62.6%) |
| Sept 2020 | - | $1.35 M(+31.2%) | $3.23 M(+72.1%) |
| June 2020 | - | $1.03 M(+22.0%) | $1.88 M(+122.0%) |
| Mar 2020 | - | $846.00 K | $846.00 K |
| Dec 2019 | $2.50 M | - | - |
FAQ
- What is Verve Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Verve Therapeutics?
- What is Verve Therapeutics annual SG&A year-on-year change?
- What is Verve Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Verve Therapeutics?
- What is Verve Therapeutics quarterly SG&A year-on-year change?
- What is Verve Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Verve Therapeutics?
- What is Verve Therapeutics TTM SG&A year-on-year change?
What is Verve Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of VERV is $49.94 M
What is the all time high annual SG&A for Verve Therapeutics?
Verve Therapeutics all-time high annual selling, general & administrative expenses is $49.94 M
What is Verve Therapeutics annual SG&A year-on-year change?
Over the past year, VERV annual selling, general & administrative expenses has changed by +$12.40 M (+33.05%)
What is Verve Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of VERV is $13.84 M
What is the all time high quarterly SG&A for Verve Therapeutics?
Verve Therapeutics all-time high quarterly selling, general & administrative expenses is $14.55 M
What is Verve Therapeutics quarterly SG&A year-on-year change?
Over the past year, VERV quarterly selling, general & administrative expenses has changed by +$2.15 M (+18.41%)
What is Verve Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of VERV is -$2.47 B
What is the all time high TTM SG&A for Verve Therapeutics?
Verve Therapeutics all-time high TTM selling, general & administrative expenses is $54.83 M
What is Verve Therapeutics TTM SG&A year-on-year change?
Over the past year, VERV TTM selling, general & administrative expenses has changed by -$2.52 B (-5137.73%)